Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helix lucorum hemocyanin is a **large, copper-containing oxygen-transport glycoprotein** derived from the hemolymph of the garden snail Helix lucorum. It acts primarily as an extracellular respiratory protein in gastropods, but demonstrates significant immunomodulatory and antitumor activities in preclinical studies. Its **mechanisms of action** include direct antiproliferative and pro-apoptotic effects on tumor cells (notably hematological cancers and certain carcinomas), as well as strong stimulation of the mammalian immune response, potentially via its xenogeneic glycan structures. Hemocyanin and its subunits from H. lucorum have shown efficacy in reducing tumor viability, suppressing tumor growth and metastasis, and prolonging survival in animal models, with observed upregulation of genes involved in apoptosis and immune activation. Structural subunits (α and βc) may display increased antitumor potency compared to the intact oligomeric complex. It is being studied as a **potential immunotherapeutic or biologic anticancer agent**, as well as for its antioxidant properties[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on helix lucorum hemocyanin.